Rophibio, Inc.
Quick facts
Phase 3 pipeline
- Eylea® Solution for intravitreal injection · Ophthalmology
Eylea (aflibercept) binds to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the eye.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: